Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Mar;28(3):213–217. doi: 10.1007/BF00204991

Combined interferon and vinblastine treatment of advanced melanoma: evaluation of the treatment results and the effects of the treatment on immunological functions

Pirkko Kellokumpu-Lehtinen 1,✉, Eeva Nordman 1, Auli Toivanen 2
PMCID: PMC11038816  PMID: 2784356

Abstract

Thirteen patients with metastatic malignant melanoma received interferon α-2a (Roferon-A) and vinblastine. The interferon dosage was increased from 3×106 IU to 9×106 IU daily in 10 weeks and thereafter 9×106 IU was administered three times weekly intrasmuscularly. Vinblastine (0.075–0.15 mg/kg) was given every third week intravenously. One of the ten evaluable patients had partial remission (PR) (11%) for 10 months. The diseases was stabilized (NC) in three patients (30%) for 3, 6 and 9 months. Progression (PD) occurred in six patients. The treatment time varied from 5 weeks to 44 weeks. The median survial time from the beginning of this combination treatment was 5 months. The most common side-effects were fever, fatigue, loss of taste, weight loss and neutropenia.

The mitogen response to phytohemagglutinin and purified protein derivative of tuberculin decreased in all patients. The response to concanavalin A decreased less and began to increase again in the patients with PR and NC. The natural killer cell activity in PD patients decreased more than in the patients with PR and NC. The ratio of T4/T8-positive cells was restored in PR + NC patients but rose in PD patients indicating a difference in the immunomodulatory effect of the combination or of the advanced disease itself on T-cell function in PD patients.

This combination of daily interferon and vinblastine did not prove to be effective in melanoma. The depression of immunological functions, which was more marked in patients with PD, might indicate that vinblastine in this combination counteracts the immunostimulatory effect of interferon.

Keywords: Melanoma, Interferon, Metastatic Malignant Melanoma, Vinblastine, Partial Remission

References

  • 1.Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analysis. Cancer. 1987;59:638. doi: 10.1002/1097-0142(19870201)59:3+<638::aid-cncr2820591312>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  • 2.Eskola J, Soppi E, Viljanen M, Ruuskanen O. A new micromethod for lymphocyte stimulation using whole blood. Immunol Commun. 1975;4:297. doi: 10.3109/08820137509055781. [DOI] [PubMed] [Google Scholar]
  • 3.Grossman Z, Herberman RB. Natural killer cells and their relationship to T-cells. Hypothesis on the role of T-cell receptor gene rearrangement on the course of adaptive differentiation. Cancer Res. 1986;46:2651. [PubMed] [Google Scholar]
  • 4.Hersey P, MacDonald M, Hall C, Spurling A, Edwards A, Coates A, McCarthy W. Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma. Cancer. 1986;57:1666. doi: 10.1002/1097-0142(19860415)57:8+<1666::aid-cncr2820571306>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  • 5.Hirsch RK, Johnson KP. The effect of long term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis. J Interferon Res. 1986;6:171. doi: 10.1089/jir.1986.6.171. [DOI] [PubMed] [Google Scholar]
  • 6.Jacqillart C, Banzet P, Maral J. Recent results in cancer research. Berlin-Heidelberg: Springer-Verlag; 1980. Clinical trials of chemotherapy and chemoimmunotherapy in malignant melanoma; p. 254. [DOI] [PubMed] [Google Scholar]
  • 7.Jones SV, Itsi LM. Safety and tolerance of recombinant interferon alfa 2-a (Roferon®-A) in cancer patients. Cancer. 1986;57:1709. doi: 10.1002/1097-0142(19860415)57:8+<1709::aid-cncr2820571315>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  • 8.Kirkwood J, Ernstoff M. Melanoma: therapeutic options with recombinant interferons. Semin Oncol. 1985;12:7. [PubMed] [Google Scholar]
  • 9.Kuzmitz R, Kokoschka EM, Micksche M, Ludwig H, Flener R. Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma. Oncology. 1985;42:26. doi: 10.1159/000226081. [DOI] [PubMed] [Google Scholar]
  • 10.Langer JA, Ortaldo JR, Petska S. Binding of human alpha-interferons to natural killer cells. J Interferon Res. 1986;6:97. doi: 10.1089/jir.1986.6.97. [DOI] [PubMed] [Google Scholar]
  • 11.McLeod GR, Thomson DB, Hersey P. Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I–II study in combination with DTIC. Int J Cancer. 1987;1:31. doi: 10.1002/ijc.2910390707. [DOI] [PubMed] [Google Scholar]
  • 12.Miller AB, Hoogstraten B, Staquet MQ, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  • 13.Pinsky CM. Clinical management of malignant melanoma. Boston: Martinus Nijhoff Publ; 1984. The immunology and immunotherapy of malignant melanoma. [Google Scholar]
  • 14.Reidnegger G, Fuchs D, Hausen A, Werner ER, Wachter H. Activated macrophages and cancer. Lancet. 1987;29:1439. [Google Scholar]
  • 15.Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  • 16.Rusthoven JJ. Clinical significance of natural killer cell cytotoxicity: need for proper data analysis in the design of clinical studies. Eur J Cancer. 1985;21:1287. doi: 10.1016/0277-5379(85)90305-0. [DOI] [PubMed] [Google Scholar]
  • 17.Spitler LE, Sagebiel R. Randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med. 1980;303:1143. doi: 10.1056/NEJM198011133032003. [DOI] [PubMed] [Google Scholar]
  • 18.Toivanen A, Granberg I, Nordman E. Lymphocyte subpopulations in patients with breast cancer after postoperative radiotherapy. Cancer. 1984;54:2919. doi: 10.1002/1097-0142(19841215)54:12<2919::aid-cncr2820541217>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  • 19.Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307:913. doi: 10.1056/NEJM198210073071503. [DOI] [PubMed] [Google Scholar]
  • 20.Veronesi U, et al. WHO collaborating centers for evaluation of methods of diagnosis and treatment of melanoma. Controlled study with imidazole carboxamide (DTIC). DTIC + bacillus Calmette-Guerin (BCG), and DTIC + Corynebacterium parvum in advanced malignant melanoma. Tumori. 1984;70:41. doi: 10.1177/030089168407000107. [DOI] [PubMed] [Google Scholar]
  • 21.West WH, Cannon GB, Kay HD, Bonnard GD, Herberman RB. Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol. 1977;118:355. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES